A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (GS-4059) and Idelalisib With and Without Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2018
At a glance
- Drugs Idelalisib (Primary) ; Obinutuzumab (Primary) ; Tirabrutinib (Primary)
- Indications Lymphoid leukaemia
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 08 Jun 2018 Planned End Date changed from 1 Aug 2023 to 1 Sep 2023.
- 08 Jun 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Mar 2019.
- 09 Nov 2017 Planned End Date changed from 1 Oct 2022 to 1 Aug 2023.